Physician profile
Eileen E Heffernan
NPI 1609862382
$4,399.00
in general payments reported to CMS, 2019-2025
40 companies · $1,256 in 2025
The $1,256 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $914 · 2021: $611 · 2022: $415 · 2023: $259 · 2024: $555 · 2025: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,069.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $664.55 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $457.92 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $420.09 | 2020-2025 | Airsupra, Breztri |
| Pfizer INC. | $275.33 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $260.50 | 2025 | Voquezna |
| Amgen INC. | $196.64 | 2019-2024 | Repatha, Evenity, Prolia |
| Allergan, INC. | $183.43 | 2020 | |
| Abbvie INC. | $182.36 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $156.50 | 2019-2025 | Spravato |
| Axsome Therapeutics, INC. | $144.82 | 2025 | Symbravo |
| Novartis Pharmaceuticals Corporation | $119.76 | 2022 | |
| Sanofi Pasteur INC. | $117.96 | 2019-2023 | |
| Novo Nordisk INC | $116.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $114.74 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $111.30 | 2025 | Zenpep |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Heffernan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.